This trial is for patients with cancer that has spread to up to 5 areas, who have a spinal instability score of 3-9, who are having the ZetaFuse bone graft implanted in their spine to help with the tumor.
8 Primary · 0 Secondary · Reporting Duration: 6 months
Experimental Treatment
10 Total Participants · 1 Treatment Group
Primary Treatment: ZetaFuse™ Bone Graft · No Placebo Group · N/A
Age 22 - 75 · Female Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: